Younes-Ibrahim M, Buffin-Meyer B, Cheval L, Burth P, Castro-Faria M V, Barlet-Bas C, Marsy S, Doucet A
Laboratoire de Biologie Integrée des Cellules Rénales, CNRS URA 1859, Commissariat à l'Energie Atomique, Saclay, France.
Braz J Med Biol Res. 1997 Feb;30(2):213-23. doi: 10.1590/s0100-879x1997000200009.
On the basis of our report that a glycolipoprotein fraction (GLP) extracted from Leptospira interrogans contains a potent inhibitor of renal Na,K-ATPase, we proposed that GLP-induced inhibition of Na,K-ATPase might be the primary cellular defect in the physiopathology of leptospirosis. The present study was designed to test this hypothesis by determining whether or not 1). GLP inhibits all the isoforms of Na,K-ATPase which are expressed in the tissues affected by leptospirosis, 2) Na,K-ATPase from leptospirosis-resistant species, such as the rat, is sensitive to GLP, 3) GLP inhibits Na,K-ATPase from intact cells, and 4) GLP inhibits ouabain-sensitive H,K-ATPase. The results indicate that in the rabbit, a leptospirosis-sensitive species, GLP inhibits with similar efficiency (apparent IC50: 120-220 micrograms protein GLP/ml) all isoforms of Na,K-ATPase known to be expressed in target tissues for the disease. Na,K-ATPase from rat kidney displays a sensitivity to GLP similar to that of the rabbit kidney enzyme (apparent IC50: 25-80 and 50-150 micrograms protein GLP/ml for rat and rabbit, respectively), indicating that resistance to the disease does not result from the resistance of Na,K-ATPase to GLP. GLP also reduces ouabain-sensitive rubidium uptake in rat thick ascending limbs (pmol mm-1 min-1 +/- SEM; control: 23.8 +/- 1.8; GLP, 88 micrograms protein/ml: 8.2 +/- 0.9), demonstrating that it is active in intact cells. Finally, GLP had no demonstrable effect on renal H,K-ATPase activity, even on the ouabain-sensitive form, indicating that the active principle of GLP is more specific for Na,K-ATPase than ouabain itself. Although the hypothesis remains to be demonstrated in vivo, the present findings are compatible with the putative role of GLP-induced inhibition of Na,K-ATPase as an initial mechanism in the physiopathology of leptospirosis.
基于我们的报告,即从问号钩端螺旋体中提取的一种糖脂蛋白组分(GLP)含有一种强效的肾钠钾ATP酶抑制剂,我们提出GLP诱导的钠钾ATP酶抑制可能是钩端螺旋体病生理病理学中的主要细胞缺陷。本研究旨在通过确定以下内容来验证这一假设:1)GLP是否抑制在受钩端螺旋体病影响的组织中表达的所有钠钾ATP酶同工型;2)来自抗钩端螺旋体病物种(如大鼠)的钠钾ATP酶对GLP是否敏感;3)GLP是否抑制完整细胞中的钠钾ATP酶;4)GLP是否抑制哇巴因敏感的氢钾ATP酶。结果表明,在对钩端螺旋体病敏感的家兔中,GLP以相似的效率(表观IC50:120 - 220微克蛋白质GLP/毫升)抑制已知在该病靶组织中表达的所有钠钾ATP酶同工型。大鼠肾脏的钠钾ATP酶对GLP的敏感性与家兔肾脏酶相似(大鼠和家兔的表观IC50分别为25 - 80和50 - 150微克蛋白质GLP/毫升),这表明对该病的抗性并非源于钠钾ATP酶对GLP的抗性。GLP还降低了大鼠髓袢升支粗段中哇巴因敏感的铷摄取(皮摩尔·毫米⁻¹·分钟⁻¹±标准误;对照组:23.8±1.8;GLP,88微克蛋白质/毫升:8.2±0.9),表明它在完整细胞中具有活性。最后,GLP对肾氢钾ATP酶活性没有明显影响,即使是对哇巴因敏感的形式也是如此,这表明GLP的活性成分对钠钾ATP酶的特异性比对哇巴因本身更高。尽管该假设仍有待在体内得到证实,但目前的研究结果与GLP诱导的钠钾ATP酶抑制作为钩端螺旋体病生理病理学初始机制的假定作用相符。